Manchester Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Manchester Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,375	Closed	-$49K	–	683
2015 Q4	$49K	Hold	2,375	–	–	0.01%	453
2015 Q3	$48K	Buy	+2,375	New	+$43.4K	0.01%	434
2014 Q4	–	Sell	-2,375	Closed	-$48K	–	1143
2014 Q3	$48K	Sell	2,375 -2,375	-50%	-$46.7K	0.01%	732
2014 Q2	$98K	Hold	4,750	–	–	0.01%	569
2014 Q1	$104K	Buy	4,750 +2,375	+100%	+$54.4K	0.02%	513
2013 Q4	$63K	Hold	2,375	–	–	0.01%	556
2013 Q3	$56K	Hold	2,375	–	–	0.01%	587
2013 Q2	$51K	Buy	+2,375	New	+$51.2K	0.01%	597

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Manchester Capital Management's VIVO Position: Q1 2016 in Review

Manchester Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2016, closing a stake of 2,375 shares — an estimated $49K sold.

Manchester Capital Management first reported a position in VIVO in Q2 2013 and held it in 8 quarters. The position peaked at $104K in Q1 2014. 172 funds tracked by Wall St. Rank hold VIVO as of Q1 2016.

Manchester Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2016 after selling out during the quarter.
Manchester Capital Management sold 2,375 Meridian Bioscience Inc shares in Q1 2016, an estimated $49K.
Manchester Capital Management first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 8 quarters.
Manchester Capital Management's Meridian Bioscience Inc position peaked at $104K in Q1 2014.
172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2016.

Based on Manchester Capital Management's 13F filing for Q1 2016, filed 4 May 2016.